About one year ago Pigs, when Clinuvel had only treated one Stroke patient, you explicitly stated that they had a realistic 5-10% chance of gaining approval in that indication. Well now with the successful completion of this Safety trial in Stroke, with some very positive efficacy to top it off, I think you should increase your probability of success to 20-25% especially since the drug is already FDA, TGA, EMA and Israel approved and Safety is regulators main priority. Furthermore, Stroke is one of the worlds big killers and it is largely untreated, so the addressable market for the drug is going to be in the multiple BILLIONS of Dollars. So that should make CUV a screaming Buy for you Pigs considering it is undervalued just on the 'proof of concept' disease EPP which is delivering some excellent profits. The chance at mega indications like DNA REPAIR and Stroke you can get for free - and you know they have a chance you have even said that!
ALL IMO DYOR
CUV Price at posting:
$15.76 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)